Roche may have scrapped work on a T-cell engager (TCE) for lupus, but the company’s head of pharma told Fierce Biotech that ...

Roche's AXELIOS 1 enters next generation DNA sequencing. Can it or rivals unseat Illumina's long-standing market dominance?

LONDON/ZURICH, June 29 (Reuters) – Roche launched its next-generation gene sequencing machine on Monday, marking a bid by the Swiss drugmaker and diagnostics group to loosen U.S.-based Illumina’s grip ...

Roche is trying to break into a relatively new market for medicines targeting a genetic mutation known as KRAS G12C that occurs in about 14% of non-small cell lung cancer cases. When working properly, ...

Roche's chief medical officer, Levi Garraway. Roche has thrown down the gauntlet to Amgen and Bristol Myers Squibb with new phase 3 data for its experimental KRAS G12C inhibitor, divarasib, which it ...

Roche’s investigational KRAS G12C inhibitor has beaten Amgen’s Lumakras and Bristol Myers Squibb’s Krazati in a phase 3 trial, furthering its ambitions to establish divarasib as a new standard of care ...

LONDON/ZURICH, June 29 (Reuters) - Roche launched its next-generation gene sequencing machine on Monday, marking a bid by the Swiss drugmaker and diagnostics group to loosen U.S.-based Illumina's grip ...